ArticleJournal of virology1996
Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 94 citations in OpenAlex.
- Article
- Distinct codon usage bias evolutionary patterns between weakly and strongly virulent respiratory viruses.iScience · 2022Article
- Adipocyte commitment of 3T3-L1 cells is required to support human adenovirus 36 productive replication concurrent with altered lipid and glucose metabolism.Frontiers in cellular and infection microbiology · 2022Article
- Adenovirus Core Proteins: Structure and Function.Viruses · 2021Review
- Viral and cellular interactions during adenovirus DNA replication.FEBS letters · 2019Review
- Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy.Biomedicines · 2019Review
- The adenovirus L4-22K protein regulates transcription and RNA splicing via a sequence-specific single-stranded RNA binding.Nucleic acids research · 2017Article
- Components of Adenovirus Genome Packaging.Frontiers in microbiology · 2016Review
- Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells.Journal of virology · 2015Article
- Regulation of human adenovirus alternative RNA splicing by the adenoviral L4-33K and L4-22K proteins.International journal of molecular sciences · 2015Review
- Adenoviral L4 33K forms ring-like oligomers and stimulates ATPase activity of IVa2: implications in viral genome packaging.Frontiers in microbiology · 2015Article
- Identification and characterization of a DNA binding domain on the adenovirus IVa2 protein.Virology · 2012Article
- Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.Human gene therapy · 2012Article
- Adenovirus late-phase infection is controlled by a novel L4 promoter.Journal of virology · 2010Article
- Unique sequence features of the Human adenovirus 31 complete genomic sequence are conserved in clinical isolates.BMC genomics · 2009Article
- Genomic analyses of recombinant adenovirus type 11a in China.Journal of clinical microbiology · 2009Article
- Adenovirus serotype 5 L4-22K and L4-33K proteins have distinct functions in regulating late gene expression.Journal of virology · 2009Article
- Adenovirus IVa2 protein binds ATP.Journal of virology · 2008Article
- Presence of the adenovirus IVa2 protein at a single vertex of the mature virion.Journal of virology · 2008Article
- Formation of a multiple protein complex on the adenovirus packaging sequence by the IVa2 protein.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adenovirus major late promoter is strongly activated after the onset of viral DNA replication. Sequence elements located downstream of the major later promoter start site have previously been shown to be essential for this activation. Two proteins (DEF-A and DEF-B) bind to these elements in a late-phase-dependent manner. DEF-B has been identified as the product of adenovirus intermediate gene IVa2 (pIVa2) (C. Tribouley, P. Lutz, A. Staub, and C. Kedinger, J. Virol. 68:4450-4457, 1994). Here we show that pIVa2, while monomeric in solution, binds to its recognition sequence as a dimer and that two 20-residue amphipathic alpha helices play an essential role in this DNA-binding activity. Attempts to purify DEF-A have failed, but its chromatographic behavior, together with its immunological properties, established that pIVa2 is also a component of this heteromeric protein. In addition, the time course of pIVa2 synthesis during infection correlated with simultaneous detection of the binding of both DEF-A and DEF-B complexes to the downstream elements. Finally, as revealed by immunomicroscopy, pIVa2 is targeted to the nucleus, where it distributes to restricted locations in the nucleoplasm, as well as to the nucleoli. Altogether, these results demonstrate that pIVa2 plays a critical role in the transition from the early to the late phase of the lytic cycle. Furthermore, pIVa2 may serve additional functions yet to be uncovered, as suggested by its presence within the cell nucleolus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.